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Summary: Neurocysticercosis (NC) remains a major public 
health problem in developing and some developed countries. 
Currently, the best procedures for diagnosing NC are neuroim- 
aging studies. Immunoserologic assays, such as enzyme-linked 
immunoelectrotransfer blot assay (EITB) or enzyme-linked im- 
munosorbent assay (ELISA), detect antibodies against Taenia 
solium, or cysticercus. Consequently, they are useful in iden- 
tifying a population at risk of contact with the parasite but do 
not necessarily indicate a systemic active infection. Most sero- 
positive individuals are asymptomatic. No data from prospec- 
tive studies concern the proportion of these individuals that will 
develop seizures or other neurologic symptoms. There is a 
discrepancy between the results of serologic assays and neuro- 
imaging studies: >SO% of those individuals with NC diagnosed 
by computed tomography (CT) scan test EITB negative. 
Pathophysiologic classification of NC into active, transi- 
tional, and inactive forms permits a good correlation between 
clinical manifestations and neuroimaging procedures and fa- 
cilitates medical and surgical management and research. The 
most frequent clinical manifestations of NC are seizures. We 
assume that NC is the main cause of symptomatic epilepsy in 
developing countries; however, no case-control or cohort stud- 
ies demonstrate this association. Most patients with NC with 
seizures have a good prognosis; nevertheless, further studies 
analyzing factors related to recurrence of seizures and possi- 
bilities of discontinuation of antiepileptic medications (AEDs) 
are needed. 
Regarding treatment of NC with antihelminthic drugs, no 
controlled clinical trials exist that establish specific indications, 
definitive doses, and duration of treatment. The most effective 
approach to taeniasis/cysticercosis infection is prevention. This 
should be a primary public health focus for developing coun- 
tries. 
We critically review the available information regarding the 
epidemiology and diagnosis of human cysticercosis, the phys- 
iopathology and imaging correlation of the parasite in the cen- 
tral nervous system (CNS) of the host, the relation between 
seizures or epilepsy and NC, and the issues surrounding the 
treatment and prognosis of NC, including the use of antihel- 
minthic therapy. Key Words: Epilepsy-cysticercosis- 
Epidemiology-Antihelminthic treatment-Imaging studies. 
At the end of the twentieth century, taeniasis and cys- 
ticercosis remain a world public health problem, not just 
in developing countries but increasingly in developed 
countries. This is due to increasing immigration from and 
more frequent travel to endemic regions (1-3). These 
parasitic diseases are related to poverty, illiteracy, and 
deficient sanitary infrastructures. For these reasons, cys- 
ticercosis has been designated a “biologic marker” of 
the social and economic development of a community 
(43. One or several parasites may go undetected in the 
brain of a host throughout his or her lifetime; alternately, 
the parasites can trigger florid symptoms. Neurocysticer- 
cosis (NC) appears to be commonly associated with 
clinical manifestations such as seizures, headaches, and 
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focal neurologic deficits, leading to long-term neurologic 
sequelae such as epilepsy, hydrocephalus, and dementia 
Whereas important advances in the diagnosis of NC 
have been achieved in the last 2 decades, many aspects 
pertaining to the natural history of the parasite infesta- 
tion, its treatment, and its prognosis still await further 
knowledge. Although the infecting mechanism is well 
known, very few, if any, preventive measures have been 
taken worldwide to eradicate cysticercosis. 
(697). 
HOST-PARASITE BIOLOGY AND 
IMMUNE RESPONSE 
Humans are the only known host of the adult cestode 
parasite Tueniu solium in the intestine. Infection is ac- 
quired by ingesting undercooked pork infected with tae- 
niae larvae (cysticerci). The cysticerci evaginate in the 
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intestines, where they mature into adult worms. The 
worms consist of a scolex, which attaches itself to the 
intestinal wall, and numerous proglottides (segments). 
Proglottides and eggs are intermittently shed into the 
stools. The intermediate host, typically the pig, is in- 
fected by ingesting parasite eggs or proglottides contain- 
ing eggs (porcine cysticercosis). The oncospheres escape 
from the eggs and penetrate the intestinal mucosa, mi- 
grating through the bloodstream and lodging in the tis- 
sues. Over a period of weeks to months, they evolve into 
larvae that enlarge and mature into cysticerci. The life 
cycle is completed when humans ingest pork contami- 
nated with cysts (8). 
Human cysticercosis is acquired from the “acciden- 
tal” ingestion of ova excreted by human tapeworm car- 
riers in their feces. In humans, the most common route of 
infection is ingestion of T solium eggs from contami- 
nated food; very rarely is infection acquired from fecal- 
oral autoinfestation in patients harboring the adult para- 
site in their intestines (9). Although cysts can develop in 
any human tissue, they have a predilection for the central 
nervous system (CNS), skeletal muscle, subcutaneous 
tissue, and the eye. The parasites arrive at the CNS via 
blood vessels and tend to locate in the richly irrigated 
gray matter. From there, the parasites migrate to the cho- 
roidal plexuses and may end up in the ventricles or the 
subarachnoid space. When the cysticerci are located in 
the CNS, the resulting disease is called NC. 
In humans and pigs, cysticerci may live within host 
tissues without causing inflammation or disease. This 
failure of living cysticerci to produce an immune re- 
sponse may be due to sequestration within immunologi- 
cally privileged sites, antigenic shifts, molecular mim- 
icry of host-like antigenic determinants, masking of 
cysticercal antigens by host immunoglobulins, and 
modulation of host immune responses (10). The immune 
response to cysticerci has been studied mainly because of 
the need for a diagnostic blood test. Although the litera- 
ture consists of numerous serologic tests carried out with 
varying degrees of scientific rigor, it is clear that virtu- 
ally all cases of symptomatic cysticercosis are associated 
with a detectable immune response (1 1,12). Infection 
with T solium often results in increased production of 
serum immunoglobulins (Igs) and formation of specific 
antibodies, mainly of the IgG class. Some patients have 
IgM, IgA, and IgE antibodies (13); however, these sub- 
class responses are less common than IgG. It is possible 
that most infected hosts produce multiple antibodies of 
different specificity that appear at different intervals after 
infection, apparently in response to the qualitative and 
quantitative changes in excretory, secretory, and somatic 
antigens during the various phases of parasitic develop- 
ment (2). 
The immunology of cysticercosis is an area of re- 
search with many intriguing questions. The response is 
unpredictable, ranging from a complete tolerance to an 
intense immune response (10,14). Moreover, a single pa- 
tient may show an intense inflammation around a cyst at 
any stage of the degeneration process, together with vi- 
able cysts without inflammation and several calcifica- 
tions scattered in the brain. Autopsies of victims of war- 
fare and road traffic accidents have revealed that a large 
proportion of NC infections are asymptomatic, discov- 
ered incidentally at necropsy (10). Frequently, multiple 
parenchymal calcifications have been incidentally de- 
tected in asymptomatic individuals during imaging stud- 
ies. These calcifications evolve from a viable cyst 
through degenerative or transitional phases. The indi- 
viduals harboring these parasites presumably have a “si’ 
lent immune response” and a remarkable tolerance to the 
parasite. 
EPIDEMIOLOGY 
There are many reasons for the difficulty in studying 
the epidemiology of NC. The natural history of the clini- 
cal aspects of NC is not completely understood. Presum- 
ably a high percentage of the population harboring NC 
remains asymptomatic (1 5-17). Among the symptomatic 
patients, the clinical manifestations of NC are polymor- 
phic, and their clinical course is unpredictable (17-21). 
The only truly reliable “gold standard” for diagnosing 
NC is pathologic confirmation through biopsy or au- 
topsy. Unfortunately, these procedures have obvious 
limitations. In spite of the fact that there are no trustwor- 
thy data concerning the specificity and sensitivity of NC 
imaging diagnostic studies, computed tomography (CT) 
scans and magnetic resonance imaging (MRI) are the 
main tools of NC diagnosis (16,19,20,22-33) and must 
be considered as close to a gold standard as we now 
have. However, these procedures are impractical for ap- 
plication in field studies because they are expensive, 
even for developed countries. Longitudinal or prospec- 
tive studies for analyzing factors associated with mor- 
bidity, ,treatment, or prognosis are also very expensive 
and time consuming. 
There are few reliable data on the prevalence of intes- 
tinal taeniasis due to T solium. Recent studies that have 
included antigen-detection assays and collection of post- 
treatment stool samples have shown that stool examina- 
tion is an insensitive method for identifying tapeworm 
carriers (34). Most publications on the frequency of NC 
(35) are based either on autopsy or biopsy materials or 
are culled from neurologic settings and general hospitals. 
Most reports fail to provide even minimal information 
regarding diagnostic criteria and definitions; conse- 
quently, these data are definitely biased and hardly rep- 
resentative of those of the general population. Serologic 
assays that use crude, nonspecific antigens have been 
used for individual diagnosis and epidemiologic surveys, 
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but they lack both sensitivity and specificity (36-38). In 
enzyme-linked immunosorbent assay (ELISA), for ex- 
ample, cross-reactions with other helminthic infection 
occur (37). Nieto (39), who designed a complement fixa- 
tion test for diagnosing NC in the cerebrospinal fluid 
(CSF), warned against the use of tests in sera due to their 
unreliability . 
An enzyme-linked immunoelectrotransfer blot assay 
(EITB) using specific glycoprotein antigens was devel- 
oped for the immunodiagnosis of human cysticercosis 
(40,4 1) with high reported sensitivity (98%) and speci- 
ficity (100%). A further study (42) confirmed the origi- 
nal results in patients with two or more cysts shown by 
CT or MRI (94% sensitivity), but sensitivity was mark- 
edly lower (28%) in patients with single enhancing cysts 
or calcifications. Some recent epidemiologic surveys for 
human cysticercosis using the EITB assay reported a 
seroprevalence of 8% in Peru (43) and 10.8% in Mexico 
(5); however, other surveys using the same procedure 
reported prevalence as high as 47.3% in India (41) and as 
low as 1.2% in Peru (44). These differences are probably 
due to the fact that the populations surveyed had differ- 
ent risks for infection (44). Most seropositive individuals 
in these populations were asymptomatic. 
There are no data from prospective studies concerning 
the proportion of seropositive individuals that will de- 
velop seizures or other neurologic symptoms. The Peru- 
vian and Mexican studies reported an association be- 
tween seizures and cysticercosis. A substantially higher 
proportion of patients with epilepsy versus those without 
were EITB positive [Peru, 12 and 3%, respectively (36); 
Mexico, 29 and 8%, respectively (5 ) ] .  Some other studies 
also reported such an association (46-49). However, the 
proportion of individuals in these studies who do not 
have epilepsy and are EITB-positive is lower than the 
proportion of seropositivity in the general population. 
Furthermore, the proportion of seropositivity in patients 
with epilepsy is more or less similar to that reported in 
the general population, in spite of the fact that similar 
methods were used by the same authors. The questions 
raised by these facts remain intriguing. A study in Gua- 
temala (50) found EITB seroprevalence to range from 10 
to 17% in rural populations but did not establish a cor- 
relation between seropositivity and a history of seizures 
or epilepsy. 
A report from Ecuador (1 3), conducted to determine 
the rate of EITB seropositivity among family members 
of patients with NC compared with those of the general 
population, showed the EITB test to be positive in 12% 
of family members and 4% of the general population (p 
< 0.05). This study confirms the high rate of seroposi- 
tivity of cysticercosis among individuals in a developing 
country and that household contacts with patients with 
NC entail a risk of acquiring cysticercosis that is three 
times higher than that of the general population. How- 
ever, only 18% of family members with a positive EITB 
test had parenchymal lesions on subsequent CT scan. 
These epidemiologic studies demonstrate a potential 
impact of cysticercosis on public health, but it should be 
noted that the presence of antibodies in the host against 
T solium or cysticercus or both does not necessarily 
mean that an individual has an active cysticercus. 
Schantz et a1 (51) found that serum antibodies (either by 
ELISA or EITB tests) were related to NC, which was 
diagnosed by CT or MRI, in only 30% of cases. A study 
in Peru (52) used the EITB assay to determine the sen- 
sitivity and specificity of the CT scan for diagnosing NC. 
This is a questionable and perhaps doubtful procedure 
because, as noted, the EITB detects systemic antibodies 
against T solium or cysticercus or both but not necessar- 
ily cysticerci in the brain. Conversely, in this same study 
(52), >50% of individuals with NC diagnosed by CT 
tested EITB negative. 
In a study of a selected rural population of 2,723 in- 
dividuals in Ecuador (46), 31 patients were diagnosed 
with epilepsy. CT scans were performed on 26 patients 
and EITB on 28 patients. NC was detected with CT in 
58% (16) of the cases; EITB was positive in only 21.4% 
of these. These results show an evident disagreement 
between CT and EITB. We believe that all these uncer- 
tainties are due, in part, to aspects related to the method 
of study, such as improper selection of patients with 
epilepsy, and lack of uniform, accurate definitions of NC 
and epilepsy (i.e., differentiation between provoked and 
unprovoked seizures). There is no reliable information 
regarding the proportion of systemic cysticercosis in in- 
dividuals who also have CNS involvement. Further stud- 
ies on the general population, randomly selected, are 
needed. 
Attempts to eradicate taeniasiskysticercosis by means 
of massive treatment with antihelminthic drugs have 
been performed in Ecuador (53) and Mexico (5435). 
These programs may produce initial beneficial results 
but have been shown to be ineffectual when reevaluated 
some years after their application (56). The prevalence of 
pork cysticercosis has diminished in many industrialized 
countries, and in some, has finally disappeared thanks to 
the modernization of hog farming and improvements in 
sanitation. However, cysticercosis, as well as T solium 
infections, are often imported into the United States and 
western Europe by immigrants, refugees, and travelers 
from countries where the infection is endemic. These 
persons may develop their first onset of NC while stay- 
ing in the country they visit or become a source of in- 
fection for local residents through fecal-oral routes of 
contamination (2,8). For example, 1.3% of the members 
of an Orthodox Jewish community in New York City 
were found to have positive EITB assays. Their seropos- 
itivity was associated with the presence of domestic em- 
ployees who were from regions of endemicity (1). 
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PATHOPHYSIOLOGY AND IMAGING 
CORRELATION OF NEUROCYSTICERCOSIS 
The natural history of the cysticerci in the CNS is not 
entirely understood. CT scans and MRIs have been use- 
ful in studying the evolution of the cysticercus within the 
brain parenchyma (22-33,57-7 1). The relation between 
imaging studies and the changes occurring in anatomy 
and pathology have been described by Escobar (9,72). In 
spite of the fact that no prospective studies show the 
differences between imaging procedures, MRI is prob- 
ably more useful than CT in detecting intraventricular 
and subarachnoideal cysts, as well as the accompanying 
signs of cyst degeneration and pericystic inflammatory 
reaction, whereas the CT scan is preferred for the detec- 
tion of parenchymal calcifications (16,22,24,29,3 1). 
Once the oncospheres are in the CNS vascular net, the 
method of penetration into the vascular wall to reach 
adjacent nervous tissue is not known. What is well es- 
tablished is that the parasite does not remain inside the 
vessel, as some authors have asserted (9). Once the on- 
cosphere has passed into the parenchyma, it grows and 
evolves through vesicular, colloidal, granular-nodular, 
and calcified phases (9,72). So far, no experimental evi- 
dence confirms this sequence; but CT scans or MRIs can 
identify these four phases. In the vesicular phase, the 
host tends to show immune tolerance. In most cases, 
there is no surrounding parenchymal reaction; the larva 
lives inside a translucent liquid-filled cystic structure 
surrounded by a thin membrane, where it can remain 
viable from a few months to several years (72,73). When 
the larva is viable, the CT scan-without enhancement 
by contrast media-depicts circumscribed, rounded, hy- 
podense areas, varying in size and number (16,22- 
26,29-32) (Figs. 1-3). The average size of the cyst is 10 
mm in diameter, but ranges from 4 to 20 mm. Larger 
cysts are identified in the ventricles. In the MRI, the 
vesicular larva appears with a cerebrospinal fluid (CSF)- 
like intensity signal on all sequences (see Figs. 1 and 3) 
and no surrounding high signal on T,-weighted images 
(27,28,33,60,67,71). Both MRI and CT may show a high 
intensity, 2-4 mm mural nodule depicting the scolex in 
the interior of some parenchymal vesicular cysts (see 
Figs. 1-3). This picture has been named “hole-with- 
eccentric dot imaging” (27) or “starry night effect” (74) 
and could be considered pathognomonic of cysticercosis; 
this phase corresponds to the active parenchymal form of 
the proposed classification of NC (29). 
Two pathologic changes take place when the host im- 
mune system reacts against the parasite (29,72). First;in 
the colloidal phase, the parasite begins to show degen- 
erative changes, the vesicular fluid takes on a gelatinous 
colloidal aspect, and the wall thickens (72). In this phase, 
the contrast-enhanced CT scan shows an annular en- 
hancement surrounded by irregular perilesional edema 
(16,22-26,29-32) (Figs. 3 and 4). The fluid content gives 
slightly higher signal than CSF and is sometimes 
isodense with the parenchyma on T, - or proton density- 
weighted images or both, and gives high signal on T,- 
weighted images (27,28,33,66,67,70,7 1). The capsule 
shows higher signal than the adjacent brain with thick 
ring enhancement on T, -weighted images, whereas on 
T,-weighted images, there is a low ring signal sur- 
rounded by high-signal lesion, due mostly to edema (33, 
66,67,70,7 1). The second pathologic change that takes 
place occurs in the nodular-granular phase. The vesicle 
tends to shrink, its content becoming semisolid as it is 
progressively replaced by granulomatous tissue (67). By 
using noncontrasted CT scan, these findings could cor- 
respond to a diffuse hypodense area with irregular bor- 
ders. After the administration of contrast media, a small, 
hyperdense, rounded, nodular image surrounded by 
FIG. 1. Typical images of cysti- 
cerci. Right: Computed tomogra- 
phy (CT) scan showing many ac- 
tive cysts with scoleces and calci- 
fications in both hemispheres; a 
ring-enhancing (transitional) cyst 
on left thalamus. Left: A T,- 
weighted image showing viable 
active cyst with a clearly defined 
scolex with pedicle. 
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FIG. 2. Postcontrast computed to- 
mography (CT) scans of a patient 
with seizures and intracranial hy- 
pertension syndrome, who received 
albendazole treatment. Right: Mul- 
tiple active cysts with the scolex in 
their interior (vesicular phase). Left: 
Twelve months after treatment, 
more cysts appeared, some of 
which increased in size. 
edema is observed (22,24,29,31; Fig. 5). In this stage, 
T,-weighted images are the most striking, as they show 
the change in the signal from the cyst fluid (27,33). The 
nodular isointense or low signal seen in some lesions is 
probably the result of early mineralization of the cyst 
associated with hyaline degeneration (72). The low sig- 
nal probably represents the marginal mineralized scolex 
inside the residual cyst, which will show as a bulls-eye 
on CT (58). In these two consecutive phases, the parasite 
shows a progressive decay; thus it cannot be considered 
either “active” or “inactive,” because of the surround- 
ing inflammatory response. It is an intermediate form 
that some authors call the “acute” (75) or “focal en- 
cephalitic” phase (65). Carpio et al. (29) argued that 
these names are somewhat ambiguous and proposed a 
new category called “transitional” because the cysticer- 
FIG. 3. Magnetic resonance images (MRI) of neurocysticercosis. Right: T,-weighted MRI shows two active cysts with the scolex in their 
interior (vesicular phase). Left: Gadolinium-enhanced T,-weighted MRI of two cysts in the transitional phase (Courtesy of Dr. Reynaldo 
Paez). 
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FIG. 4. Cysticerci in the transitional phase. Right: Postcontrast computed tomography (CT) scan shows a ring-enhancing cyst (colloidal 
phase) on left hemisphere and a nodular-enhancement image surrounded by edema (nodular-granular phase) on right hemisphere. Left: 
Proton density-weighted magnetic resonance image shows thick capsule with adjacent scolex and perilesional edema (colloidal phase). 
cus has entered into a degenerative process. Although 
these pathologic changes are associated with symptoms 
(usually seizures or headaches), they may not cause any 
symptoms at all. 
The cysts in the transitional phase may be single or 
multiple. In the latter case, if they coexist with other 
cysts in the vesicular phase and disseminated calcified 
nodules in the cerebral parenchyma, the most likely di- 
agnosis is NC (see Fig. 1). However, when there is only 
one cyst in the transitional phase, it corresponds to the 
so-called “single enhancing lesion on CT” (SECTL) 
(see Fig. 5) or hyperintense lesion on MRI, which cor- 
responds to a special syndrome discussed in more detail 
later. 
Finally, when the parasite dies, a mineralization and 
resorption process occurs, ending in a calcified nodule 
that lodges permanently in the CNS (29,72). The non- 
contrasted CT shows a rounded, homogeneous hyper- 
dense area, showing no enhancement of the contrast me- 
dia (22,24,29,31,76; see Figs. 1 and 5). In the MRI, only 
the proton density-weighted image shows a low-inten- 
sity lesion (33,66,67,70,7 1). This phase corresponds to 
the inactive parenchymal form of the proposed classifi- 
cations of NC (29,77). It is not uncommon to see mul- 
tiple calcifications disseminated in the parenchyma si- 
multaneous with viable cysts and transitional-stage 
lesions. This is a typical image of cysticercosis; 
nevertheless, when this phase coexists with other active 
or transitional phases, it is difficult to distinguish be- 
tween reinfestation during the patient’s life span and the 
varying pace of parasite evolution. 
One form of NC that has different clinical and radio- 
logic characteristics from those described is the so-called 
‘‘cysticercotic encephalitis” that occurs mainly in chil- 
dren and young women (78-81). The noncontrast CT 
image shows diffuse and intense cerebral edema and 
small or collapsed ventricles; with contrast media, mul- 
tiple, small, hyperdense, nodular, or annular images ap- 
pear disseminated throughout the whole cerebral paren- 
chyma (Fig. 6). The underlying pathology appears as an 
intense inflammatory reaction composed of lymphocytic, 
plasmocytic, and eosinophilic cell exudates (72). 
When the parasites are located in the subarachnoidal 
space or inside the ventricular system, their process of 
evolution is also different from the usual path. Surgical 
data have established that the parasites in this location 
usually remain in the vesicle stage (82-84). Being im- 
mersed in a CSF-rich environment, these cysticerci can 
evolve into the racemose form (‘ ‘Traubenhydatiden”) of 
NC (72). The racemose form constitutes a hydropic 
change that leads to large or even giant vesicles usually 
devoid of scolex; the parasite, unable to cope with the 
dropsy process, vanishes (9,72). These racemose cysts 
tend to show a rapid process of hyalinization of the cyst 
Epilepsia, Vol. 39, No. 10, 1998 
CYSTICERCOSIS AND EPILEPSY I031 
FIG. 5. Natural history of neurocysticercosis (NC). Top right: 
Parietal single nodular-enhancing lesion (transitional, nodular- 
granular phase). Top left: Six months later the lesion has disap- 
peared. Center right: Single annular-enhancing lesion (transi- 
tional, colloidal phase). Center left: Ten months later the cyst 
was replaced by a calcification. Bottom right: Large occipital 
active cyst (vesicle phase) and many small cortical cysts. Bottom 
left: After 18 months, the occipital cyst has been replaced by a 
calcification, and the  remaining cysts have disappeared. 
wall. These types of cysts are most frequently located 
either in the basal cisterns or inside the sylvian valley 
and can reach 100 mm in diameter (28,73). 
The noncontrasted CT depicts a hypodense image in 
the subarachnoid or ventricular space; the cysts deform 
the surrounding structures, and noncommunicating hy- 
drocephalus occurs (16,17,24,26). Before MRI, intraven- 
tricular NC had been diagnosed with metrizamide CT 
ventriculography (27,60,82,84); however, this is an in- 
vasive method associated with possible misdiagnosis in 
fourth-ventricle cysts (83,84). The MRI (proton or T,- 
weighted) more precisely shows the cyst as a hypoin- 
tense CSF-like image in all phases; it permits a direct 
visualization of intraventricular cysticercosis by identi- 
fying the cyst wall, scolex, or both (27,66,71). The ven- 
tricular ependymal lining reacts to the cysts, causing an 
inflammatory reaction or ependymitis, which can be vi- 
sualized by CT or MRI as a high-intensity signal in the 
ependymal layer. Gadolinium-enhanced MRI is more 
sensitive than contrast-enhanced CT to detect ependymi- 
tis (66,70,71). There is no information regarding the 
natural history of the parasite inside the ventricular sys- 
tem or the subarachnoidal space; evidence of calcifica- 
tions in these locations is scarce. From the experience of 
one of us (A.E.), racemose cysticerci tend to show easily 
hyaline degeneration of the cyst wall with an associated 
inflammatory reaction. Once the hyalinization process is 
ended, calcium salts tend to be deposited in the cyst wall, 
but slowly; how long this takes to become calcified is 
unknown. A few cases of single calcified cysticercus in 
the fourth ventricle have been found. 
When the parasite is located in the subarachnoid 
space, it also can cause a meningeal inflammatory pro- 
cess, with pleocytosis and increased protein on the CSF 
(7,29,67,70,72). The parasite degenerates to a hyaline 
mass and remains trapped inside the gummatous thick- 
ening of the leptomeninges, where the remains are sur- 
rounded by a granulomatous lesion with many multinu- 
cleated giant macrophages (9,72). Thus, identification of 
the parasites is made only by histologic examination of a 
stained section. As a sequel to this chronic intense in- 
flammatory process, fibrosis and thickening of the lep- 
tomeninges also may lead to chronic hydrocephalus. 
Viewed with the naked eye, it is difficult to differentiate 
one specimen with basal meningitis from others with 
chronic infectious pathologies (e.g., tuberculous menin- 
gitis). 
Gadolinium enhancement of MRI or contrast-enhanced 
CT clearly depict the leptomeningeal thickening along 
the cisterns ventral to the brain stem, perimesencephalic, 
and sylvian valley (66,67,85). If parenchymal calcified 
nodules coexist, the diagnosis may be indirectly rein- 
forced (29). There may be vasculitis with secondary isch- 
emic lesions (6,7,86-90). 
‘ 
CLINICAL FEATURES 
Many concepts proclaimed >50 years ago in landmark 
articles (91-98) continue with no modification. MacArthur 
(92) observed that “cysticerci while alive enjoyed a rela- 
tive tolerance on the part of the host, but after their death 
acted as foreign irritants.. . .” Lbpez-Albo (91) men- 
tioned the spontaneous resolution of seizures and their 
subsequent recurrence. Clinical manifestations of NC 
have been extensively described in classic papers (95- 
99), which conclude that they are varied and depend on 
number and localization of cysts, as well as host immune 
response to the parasite. These authors confirmed the 
diagnosis of NC mainly by means of biopsy or necropsy. 
With the advent of CT in the 1970s, diagnosis of NC was 
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improved; since then, countless publications confirmed 
that NC is characterized by clinical polymorphism, and 
that in almost every patient, the disease takes its own 
particular course. Most reports worldwide agree that the 
most frequent clinical manifestations are seizures, in- 
creased intracranial hypertension, focal neurologic defi- 
cits, and mental changes (6,7,16,86-99). Myriad syn- 
dromes were described, such as manifestations of brain 
stem dysfunction, cerebellar ataxia, sensory deficits, in- 
voluntary movements, stroke, dementia, and hydro- 
cephalus, as well as some rare and exotic symptoms 
(6,7,16,100-118). Most of these clinical manifestations 
develop over a period of a few days, weeks, or monthc, 
with periods of remission and relapse, probably due to 
different evolutionary stages of the parasite. 
Classification of NC 
Before the advent of the CT scan, several authors pub- 
lished different classifications of NC based on varied 
clinical and anatomic criteria, causing difficulties in de- 
veloping a uniform criterion for NC classification 
(100,118). A criterion based on the prognosis of the ill- 
ness as malignant or benign seems useful but limits itself 
to that particular factor of prognosis (1 19). Sotelo et al. 
(77) proposed a classification of active and inactive 
forms of NC based on the evidence of cysts in imaging 
studies or inflammatory signs on CSF analysis as an 
indication of immune activity against the parasites. In- 
cluded among the so-called active forms were cysts in a 
degenerative process. In this degenerative phase, the 
parasite is dead but there is a strong inflammatory reac- 
tion of the brain tissue adjacent to the cyst and marked 
cerebral edema; therefore, it belongs to another specific 
evolutionary stage with different clinical and therapeutic 
repercussions. 
FIG. 6. Cysticercotic encephalitis. Top: Noncon- 
trast computed tomography (CT) scans show diffuse 
low attenuation of subcortical white matter. Bottom: 
Contrast CT scans show multiple small, nodular and 
annular areas of abnormal enhancement in brain pa- 
renchyma. 
Carpi0 et al. (29) proposed an improved and widely 
accepted classification (3 1-33,7 1,108) based on the vi- 
ability and location of the parasite in the CNS of the host: 
active, when the parasite is alive, transitional if it is in the 
degenerative phase, and inactive, if there is evidence of 
its death. Each viability category was subdivided into 
parenchymal and extraparenchymal forms. The viability 
criterion is very important, as it allows us to analyze the 
natural history of the parasite, and, according to the para- 
site’s evolutionary stage, the production of physiopatho- 
logic changes in the host’s CNS. On the basis of this 
classification, it is possible to relate clinical manifesta- 
tions to each category of the proposed classification. For 
example, in a majority of 336 patients (29), seizures were 
the main symptom with active (82%) and transitional 
(88%) parenchymal forms in whom the inflammatory 
reaction of the adjacent brain tissue may also have been 
a contributing factor. On the other hand, cranial nerve 
abnormalities and intracranial hypertension syndromes 
were more frequent in meningeal forms due to the arach- 
noiditis process (Table I). 
Seizures or epilepsy as main clinical manifestation 
of NC 
Almost all authors agreed that seizures are the most 
frequent clinical manifestation of NC (91-1 18). How- 
ever, some authors (120-122) used the expression “sei- 
zures” indiscriminately for epilepsy, and vice versa. In 
fact, although all people with epilepsy experience sei- 
zures, not all individuals with seizures have epilepsy 
(123). This distinction is not only one of semantics; it is 
very important from a clinical and epidemiologic point 
of view to standardize definition criteria and to make 
studies comparable. Definitions recommended by the In- 
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TABLE 1. Classifcation and clinical manifestations in 336 
patients with neurocysticercosis" 
cases should be considered as manifesting multiple epi- 
sodes-which increase the risk of epilepsy-but they 
should not be categorized as progressive symptomatic Viability and Patients Seizure5 IH MA CNA 
location n ( % )  n ( % )  n ( % )  n ( % )  n ( % )  
Active 
Parenchymal 
Extraparenchymal 
Both 
Parenchymal 
Meningeal 
Both 
Inactive 
Parenchynial 
Meningeal 
Transitional 
Total 
90 (26.7) 74 (82) 9 (10) 
28 (8.3) 12 (43) 24 (86) 
82 (24.4) 72 (88) 15 (18) 
10 (2.9) 2 (20) 10 (100) 
18 (5.3) 6 (33) 16 (89) 
87 (25.9) 66(75) 0 
14(4.1) 7 (50) 12 (86) 
336 (100) 239 (71) 92 (27) 
7(2.1) 0 6 (86) 
IH, intracranial hypertenaion; MA, motor abnormalities; CNA, cranial nerve 
'From reference 29, Carpio et al. 
abnormalities. 
ternational League Against Epilepsy (ILAE) (124,125) 
are currently used worldwide. 
According to the definitions suggested by the ILAE 
(124,123, provoked or acute symptomatic seizures oc- 
cur in close temporal association with an acute CNS 
lesion (e.g., infection, stroke, cranial trauma). Such sei- 
zures are often isolated epileptic events associated with 
acute conditions but may also recur or occur as status 
epilepticus as the acute condition recurs. Unprovoked 
seizures (considered to be epilepsy if the seizures recur) 
may occur in relation to a well-demonstrated antecedent 
condition, substantially increasing the risk of epileptic 
seizures. Unprovoked seizures are categorized into two 
major subgroups: (a) remote symptomatic unprovoked 
seizures due to conditions resulting in a static encepha- 
lopathy, such as infection, cerebral trauma, or cerebro- 
vascular disease, which are generally presumed to be the 
result of a nonprogressive (static) lesion; and (b) symp- 
tomatic unprovoked seizures due to progressive CNS 
disorders. 
Seizures occurring with NC may be categorized under 
either provoked or unprovoked, according to its evolu- 
tionary stages. People with cysticerci in the transitional 
form or degenerative phase develop acute symptomatic 
seizures because of the inflammatory response of the 
brain; on the other hand, a patient with seizures who has 
active, viable cysts or inactive, calcified parasites or both 
may be categorized as having unprovoked seizures. 
However, because NC has an unpredictable clinical 
course, it is difficult to categorize all cases into the pro- 
posed classification of the ILAE. For instance, some pa- 
tients with chronic recurrent seizures whose imaging 
studies show several parenchymal calcifications should 
be categorized as having remote symptomatic unpro- 
voked seizures because of conditions resulting in a static 
encephalopathy. Some years later, these same patients 
could develop hydrocephalus associated with intraven- 
tricular cysts or parenchymal transitional cysts. These 
unprovoked seizures due to progressive CNS disorders. 
Neurologists from developing countries frequently see 
patients whose first seizure occurred many years earlier; 
consultation occurs only after a second seizure, at which 
time the imaging study shows one or more calcifications 
and one cyst in the transitional form with perilesional 
edema. We can assume that when the first acute seizure 
occurred, the patient had cysts in a transitional form, 
which then became calcified. By the time the second 
seizure occurs, the patient presumably has new acute 
seizures. Should the seizures be categorized as isolated 
epileptic events associated with an acute recurrent con- 
dition (e.g., a transitional form of NC) or should the 
patient be categorized as having epilepsy? According to 
the ILAE, the former is probably the most accurate clas- 
sification. Ultimately in patients with NC, differentiating 
between provoked or acute symptomatic seizures and 
recurrent unprovoked seizures (epilepsy) is vital in de- 
termining treatment and prognosis, as will be discussed 
below. One of the reasons for overdiagnosis of epilepsy 
in some studies in which there is no differentiation be- 
tween seizures and epilepsy is the inclusion of acute 
symptomatic seizures that do not evolve into epilepsy. 
There is no agreement regarding the frequency of sei- 
zure type in patients with NC. Although some authors 
reported a higher proportion of partial seizures (2 1,108, 
120), others concluded that generalized seizures occur 
more frequently (81,122). These discrepancies may be 
due to such methodologic problems as described. In gen- 
eral, it seems that about half the cases are partial epilepsy 
and the other half generalized epilepsy, a proportion 
similar to that of the general population (1 26,127). 
NC and the etiology of epilepsy 
Studies of etiology of epilepsy in developing countries 
are few. Those that exist are of all seizures rather than 
epilepsy alone, and most are prevalent case series, which 
are not useful in identifying the cause of seizures. Nev- 
ertheless, the available information shows that the ratio 
of idiopathic (60-70%) to symptomatic (3040%) epi- 
lepsy remains constant in comparison with studies from 
developed countries (128). Among the symptomatic 
group, infection and parasitic diseases-in particular 
neurocysticercosis, perinatal brain damage, and head 
trauma-are the most frequent disorders reported as a 
cause of epilepsy (105,128,129). It is extremely difficult 
to compare results of studies of epilepsy due to NC. In 
addition to broad differences in the definition (if any) of 
NC, there is also a failure to define criteria for diagnosis 
of either seizures or epilepsy. There is no information on 
the latency between the first acute symptomatic seizure 
and the first unprovoked seizure, and not even informa- 
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tion on the relative age of the patient at the time of onset 
of seizures and the time of diagnosis of NC. 
Although NC is often cited as a major cause of epi- 
lepsy in countries where T solium is endemic (7,96,100, 
120-122,130), few accurate data are available. There is 
anecdotal information as to the relation between epilepsy 
and cysticercosis in New Guinea (1 3 1,132), where cys- 
ticercosis was introduced by imported pigs in 1972, and 
there was an apparent increase in the number of burns 
that occurred when individuals having seizures fell into 
open fires, which are commonly used in this population. 
In a study from India (133), in which acute symptomatic 
seizures were excluded, only 5.3% of 253 patients with 
epilepsy had NC. Studies of highly selected patients with 
epilepsy (or seizures?) in hospital settings from Latin 
American countries (1 20-1 22), whose diagnoses were 
based on CT, report NC as the cause of epilepsy in 30- 
50% of patients. Surprisingly, the proportion of epilepsy 
cases associated with cysticercosis using an immunose- 
rological test as a diagnostic tool is considerably lower 
than the proportion of NC cases using CT as a diagnostic 
tool. Only 12% of patients with epilepsy attending an 
outpatient clinic in Peru had serological evidence of T 
solium as shown by the EITB test (41,44). 
Single inflammatory lesion and seizures 
Single enhancing lesion on CT (SECTL), or hyperin- 
tense lesion on MRI, is a common finding in patients 
with seizures from developing countries. The lesion is 
usually small (-5-10 mm), well defined, annular or 
nodular contrast enhancing, cortical or subcortical, and 
generally associated with perilesional edema and mini- 
mal mass effect, but without any midline shift (see Fig. 
5). The patients-mainly children and young adults- 
have some benign and transitory clinical manifestations, 
predominantly partial or partial secondarily generalized 
seizures, and, occasionally, Todd’s paresis or focal neu- 
rologic deficits. The results of biopsy of these lesions 
have reported varied etiologies: cysticercus, tuberculo- 
mas, pyogenic abscess, meningoencephalitis, and even 
normal brain. In the majority of cases there were inflam- 
matory changes; therefore, the name single inflammatory 
lesion (SIL) seems justified in referring to both the 
SECTL shown on CT and the hyperintense lesion shown 
on MRI. These lesions were described in the 1980s as a 
common neurologic syndrome in patients with epilepsy 
in India (63,64,134-138). They were also included in the 
neurocysticercosis literature of the West using a different 
nomenclature: ‘‘acute or focal encephalitic stage’ ’ ( 6 3 ,  
“solitary parenchymal lesions” (68,75), ‘‘acute lesions’ ’ 
(58),  “single transitional forms” (29), or, simply, “cys- 
ticercosis granulomas” (24,138). The etiology of these 
lesions has been attributed mainly to cysticercosis 
(138,139) and tuberculosis (140); however, similar le- 
sions have been reported in other inflammatory patholo- 
gies, such as in cases of pyogenic abscess (141); histo- 
plasmosis, blastomycosis, and sarcoidosis (24); postin- 
fectious vasculitis; and primary and metastatic brain 
tumors (142). A vascular etiology was also argued (134): 
Cryptic or angiographically occult small vascular mal- 
formations such as cavernous angiomas could produce 
seizures and radiologically resemble SECTL; neverthe- 
less, this assumption is no longer supported. Some au- 
thors believe that SECTL may be the result of seizures 
(143,144), which cause vasogenic edema resulting in the 
surrounding hypodensity; the enhancement may repre- 
sent a break in the blood-brain barrier. However, CT 
scans performed 2 2  weeks after a seizure display 
SECTL, an indication that the seizure is not a trigger for 
the images on CT or MRI. 
Initially, SIL had been labeled as intracranial tubercu- 
lomas (137,140). In some cases the diagnosis was 
achieved by biopsy but mostly by the disappearance of 
this lesion after therapy with antituberculous drugs or on 
the circumstantial evidence of tuberculous lesions else- 
where in the body. It was later noticed that, in most 
cases, these lesions disappeared or became calcified 
merely on treatment with anticonvulsant medications 
(AEDs; 63,134,136). Sethi et al. (134) reported a series 
of patients presenting partial seizures in which initial 
CTs showed a SECTL; on follow-up CT scans after 6 to 
24 weeks of no specific treatment except AED, these 
abnormalities had disappeared. Other authors (143,144) 
also reported patients with partial seizures in whom CT 
demonstrated similar reversible abnormalities. Chandy et 
al. (145) reported a series of 30 patients in India with 
SECTL. On 10 patients (group B), a CT-guided stereo- 
taxic biopsy was performed. On 15 patients (group C), an 
excision biopsy was performed. In all patients in group 
B, the lesions were reported as “chronic nonspecific in- 
flammation,” whereas seven of 15 patients in group C 
showed a cysticercus. Biopsy did not reveal a tubercu- 
loma in any of these patients. The authors concluded 
that, in India, cysticercosis is the most common etiology 
in patients with epilepsy and SECTL. 
Based on the assumption that the two most commonly 
considered diagnoses for SIL in patients from endemic 
areas ‘are cysticercus or tuberculoma, Rajshekar et al. 
(146) attempted to identify features that may distinguish 
these two disease processes. They validated some diag- 
nostic clinical and CT criteria for “solitary cerebral cys- 
ticercus granuloma” in patients with seizures. The clini- 
cal criteria are seizures as the initial symptom, with no 
evidence of persistent raised intracranial pressure, no 
progressive neurologic deficit, and no active systemic 
disease. The CT diagnostic criteria are evidence of a 
solitary contrast-enhancing lesion measuring c 2 0  mm, 
without a shift of the midline structures due to surround- 
ing edema. The authors compared these criteria with a 
“gold standard” also based on clinical and radiologic 
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grounds; therefore, the results could be questionable. The 
same authors (64) retrospectively compared visualization 
of ‘‘solitary cerebral cysticercus granulomas” on con- 
trast-enhanced CT and MRI in 16 patients with seizures. 
MRI did not reveal additional granulomas or cysts in any 
of their patients, thus precluding the concern that MRI 
might reveal more lesions in patients in whom CT shows 
a solitary granuloma or transitional cyst. The natural his- 
tory of SIL can usually take one of two forms: (a) it 
becomes isodense on CT or isointense on MRI and may 
be resolved entirely; or (b) a punctuate calcification may 
be left as a residue (see Fig. 5). The duration or time of 
resolution of the lesion seems to be quite variable, from 
a few weeks to >I year (29,75,134,135,145,147), which 
leads us to think that the main etiology of SIL is NC. 
Based on the assumption that SIL is cysticercus, Rawl- 
ings et al. (148) empirically administered praziquantel, 
assuming that anticysticercal drugs would accelerate the 
resolution of the parasite. Later, other authors duplicated 
this procedure by using albendazole (149,150). Unfortu- 
nately, the latter authors did not perform a randomized, 
double-blind, placebo-controlled design. Padma et al. 
(151) reported the results of a clinical trial involving 75 
patients (from age 3.5 to 50 years) with seizures and 
SECTL due to NC. Patients were randomized to receive 
albendazole or placebo. At the end of a 3-month follow- 
up, 35 of 40 patients who received albendazole and 33 of 
35 patients who received placebo showed resolution of 
the lesions on CT scan. The authors thus concluded that 
the albendazole therapy was unnecessary. 
Regarding the management of patients with SIL, in 
spite of the fact that spontaneous resolution of SECTL 
was reported early in 1985 (134) and that indisputable risks 
are related to brain biopsy, this procedure is still frequently 
used to confm diagnosis (134,137,141,142,147,152-154). 
Complementary tests must be performed to discard eti- 
ologies other than NC. At present, the transitional forms 
of parenchymal cysticercosis are considered the stage 
associated with SIL. The lesions are benign and tend to 
resolve spontaneously, making anticysticercal drugs or 
surgery unnecessary because the parasite is already in the 
degenerative phase and will eventually disappear or be- 
come calcified. The symptoms should be controlled by 
treatment such as AEDs (57,68,155-161). 
EFFECT OF ANTICYSTICERCAL TREATMENT 
ON EPILEPSY 
Although the first reports regarding treatment for NC 
with antihelminthic drugs such as metriphonate (162), 
mebendazole (163), fluobendazole (164), praziquantel 
(165), and albendazole (166) were published >15 years 
ago, there are no controlled clinical trials to establish the 
specific indications, definitive doses, and duration of 
treatment (155). Whereas it is generally assumed that 
either praziquantel or albendazole is an effective treat- 
ment for NC (166-176), a critical review of the literature 
suggests that the studies on which these assumptions are 
based are flawed in terms of patient selection, assign- 
ment to treatment, and selection and measurement of 
outcome variables (160,161,177). Many authors (176- 
183) appropriately criticized the publications on this 
topic to date and concluded that no adequate studies of 
efficacy have been reported. Other authors warned that, 
in some patients, antihelminthic therapy might be harm- 
ful, particularly in the subarachnoideal localization, be- 
cause these drugs might cause arachnoiditis and arteritis, 
and consequently hydrocephalus (1 84,185). 
A randomized clinical trial was performed on patients 
with newly identified active NC (156). Oral prednisolone 
alone (randomized to 27 patients) was compared with 
praziquantel and prednisolone (in 54 patients), or al- 
bendazole with prednisolone (in 57 patients). At 6 
months and 1 year after treatment, there were no differ- 
ences in the three treatment groups in terms of the pro- 
portion of cases free of cysts or the relative reduction of 
number of cysts. At 2 years, there was no difference in 
the proportion of cases free of seizures over the entire 
follow-up period (Table 2 ) .  According to these results, 
treatment with antihelminthic drugs does not modify the 
prognosis of seizures in patients with NC. This study, the 
largest single trial of NC treatment reported to date, ad- 
TABLE 2. Treatment of neurocysticercosis: Number (proportion) of cases with disappearance of cysts on computed tomography 
(CT) scan within treatment groups, and clinical outcomeu 
CT scanb 
Albendazole group 
n (%) 
Praziquantel group 
n (%) 
Control group 
n (%) 
Single cyst FOIIOW-LIP 1
Follow-up 2 
Multiple cysts Follow-up 1 
Follow-up 2 
All cysts Follow-up 1 
Freedom from seizures 
Follow-up 2 
9 (39.1) 
13 (56.5) 
7 (20.6) 
14 (41.2) 
16 (28.1) 
27 (47.4) 
33 (63) 
10 (50) 
14 (70) 
7 (20.6) 
11 (32.4) 
17 (31.5) 
25 (46.3) 
26 (58) 
5 (41.7) 
7 (58.3) 
0 
3 (20) 
5 (18.5) 
10 (37) 
12 (57) 
p value‘ 
0.76 
0.64 
0.1 
0.34 
0.46 
0.65 
0.61 
a From reference 156, Carpi0 et al. 
*Follow-up 1 ,  CT scan 3-6 months after treatment; follow-up 2, CT scan 9-12 months after treatment. 
x2 test. 
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dresses questions as to what extent and in which patients 
treatment with either praziquantel or albendazole is ef- 
fective (see Fig. 2). The improvement attributed to anti- 
helminthic drugs in previous studies may be related to 
the lack of appropriate controls and is likely to be a 
reflection of the natural history of NC (see Fig. 5). The 
authors pointed out the need to conduct a long-term, 
placebo-controlled trial with precise end points, proper 
randomization, sample-size calculations, and predeter- 
mined statistical calculations to evaluate properly the ef- 
fectiveness and determine the indications of etiologic 
treatment for NC. 
Some authors suggested that the control of seizures in 
patients with NC is better after a course of anticysticercal 
drugs than when the disease is left untreated (12 1,186) 
and that the chance of remaining seizure free after the 
withdrawal of AEDs seems to be greater in those patients 
who were previously treated with anticysticercal drugs 
(187). Another presumed effect of anticysticercal drugs 
is the normalization of the cellular immune functions 
(188). Again, such studies are flawed by lack of control 
groups or accurate patient selection. For example, in one 
study (121) seizures were reported to remit after treat- 
ment with praziquantel or albendazole but persisted in an 
untreated group selected from patients attending clinics 
for people with chronic and untreatable epilepsy. Al- 
though there was a decrease in the frequency of seizures 
in patients who received antiparasitic therapy, it is not 
clear that this was a result of therapy or of patient selec- 
tion bias (1 82). 
To our knowledge, there are no studies that separate 
NC patients with acute symptomatic seizures from pa- 
tients with chronic recurrent seizures and patients with 
newly diagnosed recurrent seizures. We think these dis- 
tinctions are crucial to select patients properly; other- 
wise, selection may be a main source of bias. 
PROGNOSIS OF PATIENTS WITH EPILEPSY 
DUE TO NC 
More than 50 years ago, Dixon and Lipscomb (96) 
observed that many patients with NC and epilepsy im- 
proved spontaneously and that “the prognosis is much 
better than has hitherto been thought.” Many authors 
affirm that most NC patients with seizures or epilepsy 
have a good prognosis (68,134,156,158,189-191). How- 
ever, at present there are no prospective cohort studies to 
ascertain the prognosis of NC. It can be assumed that 
prognosis of NC patients with epilepsy is similar to the 
figures of symptomatic epilepsy reported in well-known 
studies (123,192-196). Hauser and Hesdorffer (123) re- 
ported that, after an initial unprovoked seizure, seizures 
recurred among 16-61 % of patients. The risk of recur- 
rence increases among patients with a remote symptom- 
atic etiology (as in the case of NC), partial seizures, and 
an abnormal EEG. In a recent study, Cockerel1 et al. 
(197) reported that 61% of patients with remote symp- 
tomatic seizures achieved a 5-year remission. 
Prospective studies regarding the discontinuation of 
AEDs in patients with NC are also lacking. In a retro- 
spective study (187) in which AEDs were tapered in 40 
patients with epilepsy caused by NC who had been free 
of seizures for 2 years, there was an overall relapse rate 
of 50%. The author suggested that patients with recurrent 
seizures before the start of albendazole therapy have the 
highest rate of relapse; however, these results were not 
compared with a control group. Besides, the reported rate 
is similar to those reported by Berg and Shinnar (198, 
199) in a recent meta-analysis, in which the discontinu- 
ation of AEDs is associated with a 12-67% risk of re- 
lapse. There is no evidence that NC increases the risk of 
recurrent unprovoked seizures. In a reported case- 
control study of risk factors in 25 patients with epilepsy, 
Gracia et al. (200) did not find NC to be a risk factor for 
epilepsy when it was tested in serum. 
So far, there are no studies specifically designed ac- 
cording to modern methods of epidemiology-either ret- 
rospective case-control or prospective cohort studies- 
that analyze factors associated with recurrence or remis- 
sion of seizures in patients with NC. It is therefore 
impossible to establish how long treatment is needed 
before discontinuation of AEDs. Seizures due to in- 
flamed cysticercal lesions should be considered acute 
symptomatic seizures. Therefore patients should be 
treated only for the duration of the acute condition, per- 
haps several months during which the inflammatory re- 
sponse is active (201). Once the lesion has resolved on 
neuroimaging and the EEG is normal, AEDs may be 
tapered. If seizures recur, AEDs should be restarted, and 
the patient may be treated for 1-2 years. If the patient has 
seizures and calcified lesions, treatment should last 1-2 
years before being reduced (201). If this is the case, these 
general recommendations of management of symptom- 
atic epilepsy, regardless of a specific etiology, should be 
followed. 
Cysticercosis is a disease of poverty and social under- 
development. Human cysticercosis may be prevented by 
improvements in sanitation, health care, and socioeco- 
nomic status. Until the condition is prevented, collabo- 
rative studies in endemic countries should be performed. 
To improve the knowledge of this parasitic disease, simi- 
lar study methodology and definitions should be used. 
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